NCT00064467 - Lethargic Depression Study | Biotech Hunter

Enrollment

268

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions

EpilepsyMajor Depressive Disorder (MDD)

Interventions

DRUG

Extended-release bupropion (HCl)

Trial Locations (24)

20852

GSK Investigational Site, Rockville

30060

GSK Investigational Site, Marietta

33156

GSK Investigational Site, Miami

39157

GSK Investigational Site, Ridgeland

44122

GSK Investigational Site, Beachwood

48336

GSK Investigational Site, Farmington Hills

52401

GSK Investigational Site, Cedar Rapids

60523

GSK Investigational Site, Oak Brook

75231

GSK Investigational Site, Dallas

77004

GSK Investigational Site, Houston

77566

GSK Investigational Site, Lake Jackson

78229

GSK Investigational Site, San Antonio

78746

GSK Investigational Site, Austin

80212

GSK Investigational Site, Denver

87108

GSK Investigational Site, Albuquerque

90210

GSK Investigational Site, Beverly Hills

91403

GSK Investigational Site, Sherman Oaks

92591

GSK Investigational Site, Temecula

97201

GSK Investigational Site, Portland

06416

GSK Investigational Site, Cromwell

06518

GSK Investigational Site, Hamden

06457

GSK Investigational Site, Middletown

08057

GSK Investigational Site, Moorestown

02865-4208

GSK Investigational Site, Lincoln